BioLineRx Ltd. (BLRX) stock analysis
Healthcare · Biotechnology
From the 20-F filed 2026-03-23
How it makes money
Partners pay royalties and milestones to BioLineRx for its drug partnerships.
BioLineRx earns money by out-licensing its therapies to third-party companies. These partners manage the actual selling of the drugs.
In return, BioLineRx receives payments when the partners achieve specific milestones or generate sales.
What protects it: the moat
Management claims its disciplined in-licensing process protects the pipeline.
BioLineRx attempts to select therapeutic candidates with a high probability of success. This is done through a systematic process of scientific and clinical validation.
What growth costs
Capital expenditures for the year ended December 31, 2023 were $0.3 million.
Current spending involves acquiring laboratory and communications equipment. However, the company expects research and development activities to expand over time.
What could damage it
Lack of reimbursement from third-party payors could impair earnings.
Even if a drug is approved, medical insurance or government programs might not pay for it. If customers are not reimbursed, they will not buy the drugs.
About BioLineRx Ltd.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.